MedTrace Logo

Effects of Intact and Disrupted Milk Fat Globule Membrane on Postprandial Metabolic Response to High-fat Dairy in Healthy Individuals

NCT06340412 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-03-06

No results posted yet for this study

Summary

The aim of the study is to investigate the effects of milk fat globule membrane (MFGM) content and intactness on postprandial metabolic response to a high-fat meal in humans.

The investigators hypothesize that MFGM content and intactness alters the postprandial lipid profile and substrate metabolism in healthy individuals after consumption of a high-fat meal.

Conditions

  • Postprandial Lipid Metabolism

Interventions

DIETARY_SUPPLEMENT

Sandwich with butter-like dairy product (40g milk fat) with intact MFGM. One sandwich for breakfast and one sandwich for lunch.

1\) Sandwich with butter-like dairy product (40g milk fat) with intact MFGM.

DIETARY_SUPPLEMENT

Sandwich with butter-like dairy product (40g milk fat) with disrupted MFGM. One sandwich for breakfast and one sandwich for lunch.

2\) Sandwich with butter-like dairy product (40g milk fat) with disrupted MFGM.

DIETARY_SUPPLEMENT

Sandwich with butter-like dairy product (40g milk fat) without MFGM. One sandwich for breakfast and one sandwich for lunch.

3\) Sandwich with butter-like dairy product (40g milk fat) without MFGM.

Sponsors & Collaborators

  • Arla Foods

    collaborator INDUSTRY

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Esben Søndergaard, MD, PhD · Steno Diabetes Center Aarhus, Denmark

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-03-11
Primary Completion
2024-12-01
Completion
2025-03-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06340412 on ClinicalTrials.gov